Image

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting
18 - 75 years of age
Both
Phase 1/2

Powered by AI

Overview

This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.

Eligibility

Inclusion Criteria:

  1. Subjects voluntarily participate in this study and sign informed consent.
  2. Expected survival ≥3 months.
  3. Patients with advanced solid tumors (including advanced Well differentiated/dedifferentiated liposarcoma) who cannot be treated by radical surgery/other local treatment.
  4. According to RECIST v1.1, participants in the dose expansion phase must have at least one measurable lesion.
  5. The laboratory test results meet the organ function requirements before starting the study treatment.
  6. Prior to the start of the study treatment, the peripheral nerve toxicity of previous anti-tumor drug treatment had returned to ≤ grade 2, and other reversible toxic reactions had returned to ≤ grade 1, but hair loss/pigmentation and other effects were assessed by the investigator as beneficial to the subjects receiving the study treatment. The toxicity of the risk is not subject to this limitation.
  7. Subjects agree to use effective contraception from the time they sign the informed consent to the last time they use the study drug.

Exclusion Criteria:

  1. Taking anti-tumor traditional Chinese medicines at the time of signing the ICF.
  2. Had undergone surgery prior to treatment and hasn't yet recovered from adverse effects of surgery.
  3. Had a history of other malignancies before starting the study.
  4. History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; NYHA Class ≥II; QTcF≥ 470 ms; LVEF≤ 50%.
  5. Diseases affecting drug administration or gastrointestinal absorption before the start of the study and assessed by the investigators could not be included in the study.
  6. Previous history of organ transplantation.
  7. Before starting the study, HBsAg positive patients with HBV DNA > 500IU/ mL or 2500 copies /mL or the lower limit of the study center detection, or HCV antibody positive patients with HCV RNA positive, or known HIV-infected patients, or known active tuberculosis.
  8. Accompanied by any other serious, progressive, or uncontrolled disease.
  9. Subjects with a known history of immune-related adverse events that the investigator determined could not be included.
  10. History of severe allergic disease, history of severe drug allergy, or known allergy to any component of the investigational product.
  11. Women who are pregnant or breastfeeding.
  12. Any other reason for which patients are ineligible for the study as assessed by the investigator.

Study details

Advanced Solid Tumors

NCT05944224

Shanghai Pharmaceuticals Holding Co., Ltd

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.